Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM) [Yahoo! Finance]
Aytu BioPharma, Inc. (AYTU)
NASDAQ:AMEX Investor Relations:
aytubio.com/investors/stock-information
Company Research
Source: Yahoo! Finance
Full year fiscal 2025 adjusted EBITDA of $9.2 million $31.0 million cash balance at June 30, 2025 Exclusive agreement in June 2025 to commercialize EXXUA™ (gepirone) extended-release tablets ("EXXUA") is expected to serve as a major growth catalyst; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market with what the Company believes to be a novel first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD Company to host conference call and webcast today, September 23, 2025, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / September 23, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced
Show less
Read more
Impact Snapshot
Event Time:
AYTU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AYTU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AYTU alerts
High impacting Aytu BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AYTU
News
- Aytu BioPharma (NASDAQ:AYTU) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Strong ADHD Portfolio Performance ... [Yahoo! Finance]Yahoo! Finance
- Aytu BioPharma, Inc. (AYTU) Q1 2026 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Aytu BioPharma (NASDAQ:AYTU) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Aytu BioPharma to Present at Upcoming October 2025 Conferences [Yahoo! Finance]Yahoo! Finance
AYTU
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- 10/24/25 - Form ARS
- AYTU's page on the SEC website